Modality
siRNA
MOA
EZH2i
Target
RET
Pathway
DDR
Cervical Ca
Development Pipeline
Preclinical
~May 2013
→ ~Aug 2014
Phase 1
~Nov 2014
→ ~Feb 2016
Phase 2
~May 2016
→ ~Aug 2017
Phase 3
Nov 2017
→ Oct 2031
Phase 3Current
NCT03493064
1,960 pts·Cervical Ca
2017-11→2031-07·Not yet recruiting
NCT06091288
2,503 pts·Cervical Ca
2021-09→2031-10·Completed
NCT07103213
2,303 pts·Cervical Ca
2023-11→TBD·Terminated
6,766 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2031-07-165.3y awayPh3 Readout· Cervical Ca
2031-10-275.6y awayPh3 Readout· Cervical Ca
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Not yet…
P3
Complet…
P3
Termina…
Catalysts
Ph3 Readout
2031-07-16 · 5.3y away
Cervical Ca
Ph3 Readout
2031-10-27 · 5.6y away
Cervical Ca
CompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03493064 | Phase 3 | Cervical Ca | Not yet recr... | 1960 | UPCR |
| NCT06091288 | Phase 3 | Cervical Ca | Completed | 2503 | Safety |
| NCT07103213 | Phase 3 | Cervical Ca | Terminated | 2303 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF |